Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Mitsudomi

Showing results (131-140 of 336) with videos related to

Pageof 34
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2010
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancerKenichi Suda, Isao Murakami, Tatsuya Katayama, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2017
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer TransformationKenichi Suda, Isao Murakami, Hui Yu, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2003
The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene statusTakeshi Suzuki, Taku Nakagawa, Hideki Endo, et al.
Japanese Journal of Clinical Oncology|April 16, 2013
Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405)Hiroaki Akamatsu, Akira Inoue, Tetsuya Mitsudomi, et al.
Lung Cancer (Amsterdam, Netherlands)|January 3, 2013
Solitary pulmonary metastasis from lung cancer harboring EML4-ALK after a 15-year disease-free intervalKenji Tomizawa, Simon Ito, Kenichi Suda, et al.
Plos One|April 22, 2016
Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL ExpressionKatsuaki Sato, Kenichi Suda, Shigeki Shimizu, et al.
Clinical Lung Cancer|November 25, 2021
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN TrialJohn V Heymach, Tetsuya Mitsudomi, David Harpole, et al.
Clinical Drug Investigation|December 17, 2017
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKIHelen Mann, Frank Andersohn, Carolyn Bodnar, et al.
Cancer Research|April 23, 2009
Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analysesHiromichi Ebi, Shuta Tomida, Toshiyuki Takeuchi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2007
Factors involved in lymph node metastasis in clinical stage I non-small cell lung cancer--from studies of 604 surgical casesNobukazu Fuwa, Tetsuya Mitsudomi, Takashi Daimon, et al.
Pageof 34

Showing results (131-140 of 336) with videos related to

Sort By:
Pageof 34
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2010
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancerKenichi Suda, Isao Murakami, Tatsuya Katayama, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2017
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer TransformationKenichi Suda, Isao Murakami, Hui Yu, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2003
The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene statusTakeshi Suzuki, Taku Nakagawa, Hideki Endo, et al.
Japanese Journal of Clinical Oncology|April 16, 2013
Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405)Hiroaki Akamatsu, Akira Inoue, Tetsuya Mitsudomi, et al.
Lung Cancer (Amsterdam, Netherlands)|January 3, 2013
Solitary pulmonary metastasis from lung cancer harboring EML4-ALK after a 15-year disease-free intervalKenji Tomizawa, Simon Ito, Kenichi Suda, et al.
Plos One|April 22, 2016
Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL ExpressionKatsuaki Sato, Kenichi Suda, Shigeki Shimizu, et al.
Clinical Lung Cancer|November 25, 2021
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN TrialJohn V Heymach, Tetsuya Mitsudomi, David Harpole, et al.
Clinical Drug Investigation|December 17, 2017
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKIHelen Mann, Frank Andersohn, Carolyn Bodnar, et al.
Cancer Research|April 23, 2009
Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analysesHiromichi Ebi, Shuta Tomida, Toshiyuki Takeuchi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 19, 2007
Factors involved in lymph node metastasis in clinical stage I non-small cell lung cancer--from studies of 604 surgical casesNobukazu Fuwa, Tetsuya Mitsudomi, Takashi Daimon, et al.
Pageof 34